Aerie Pharmaceuticals Inc (AERI) Position Increased by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans lifted its holdings in shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 9.6% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 106,559 shares of the company’s stock after purchasing an additional 9,373 shares during the period. Thrivent Financial for Lutherans owned 0.23% of Aerie Pharmaceuticals worth $3,847,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the company. Bank of Montreal Can boosted its stake in shares of Aerie Pharmaceuticals by 40.2% during the 4th quarter. Bank of Montreal Can now owns 1,060 shares of the company’s stock worth $38,000 after acquiring an additional 304 shares during the period. Pearl River Capital LLC acquired a new stake in Aerie Pharmaceuticals during the 4th quarter worth approximately $59,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Aerie Pharmaceuticals by 23.0% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,753 shares of the company’s stock worth $99,000 after purchasing an additional 515 shares during the last quarter. Amundi Pioneer Asset Management Inc. acquired a new stake in Aerie Pharmaceuticals during the 4th quarter worth approximately $105,000. Finally, Xact Kapitalforvaltning AB lifted its holdings in Aerie Pharmaceuticals by 31.3% during the 4th quarter. Xact Kapitalforvaltning AB now owns 7,551 shares of the company’s stock worth $273,000 after purchasing an additional 1,800 shares during the last quarter.

Several brokerages have weighed in on AERI. BidaskClub raised Aerie Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, April 4th. Canaccord Genuity lowered their price target on Aerie Pharmaceuticals from $86.00 to $73.00 and set a “buy” rating for the company in a report on Tuesday, March 5th. ValuEngine raised Aerie Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, March 1st. Zacks Investment Research cut Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, March 15th. Finally, Oppenheimer restated a “buy” rating on shares of Aerie Pharmaceuticals in a research report on Tuesday, March 19th. Two analysts have rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company. Aerie Pharmaceuticals has a consensus rating of “Buy” and an average target price of $76.50.

AERI stock traded down $0.61 during trading on Friday, reaching $39.17. 623,975 shares of the stock were exchanged, compared to its average volume of 528,615. Aerie Pharmaceuticals Inc has a twelve month low of $32.18 and a twelve month high of $74.75. The company has a market cap of $1.80 billion, a P/E ratio of -8.42 and a beta of 0.96.

In other news, insider Casey C. Kopczynski sold 11,000 shares of the stock in a transaction that occurred on Friday, February 1st. The stock was sold at an average price of $46.17, for a total value of $507,870.00. Following the completion of the sale, the insider now directly owns 97,243 shares of the company’s stock, valued at $4,489,709.31. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 10.53% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.baseballdailydigest.com/news/2019/04/21/thrivent-financial-for-lutherans-acquires-9373-shares-of-aerie-pharmaceuticals-inc-aeri.html.

Aerie Pharmaceuticals Profile

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Further Reading: The Role of a Fiduciary and Individual Investors

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.